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High Cure Rate W ith  a M o d era te ly  In te n s iv e  T rea tm en t  
Regim en in N on —H igh -R isk  C h ild h o o d  A cu te  
L ym phoblastic  L eukem ia: R esu lts  o f  P r o to c o l  A L L  VI  
From  the Dutch C hild hood  L e u k e m ia  S tu d y  G rou p
By A.J.P. Veerman, K. Hahlen, W.A. Kamps, E.F. Van Leeuwen, G.A.M. De Vaan, G. Solbu/ S. Suciu,
E.R. Van Wering, and A. Van der Does-Van den Berg
Purpose: Here we report the results of a nationwide 
cooperative study in the Netherlands on acute lympho- 
blastic leukemia (ALL) in children. The aim of the study 
was to improve the cure rate and to minimize side effects 
in a group of non-high-risk ALL patients, especially with 
regard to the CNS. A second aim w as to study potential 
prognostic factors.
Methods: Children (age 0 to 15 years) with non-h igh- 
risk ALL (WBC count <  50 x 109/L, no mediastinal mass, 
no B-cell phenotype, and no CNS involvement) were 
treated with a uniform protocol, ALL VI. The treatment 
protocol used 6-week induction regimen with three drugs 
(vincristine, dexamethasone, and asparaginase), three 
weekly doses of intravenous (IV) medium high-dose 
methotrexate (2 g/m 2), and 2-year maintenance therapy 
that consisted of alternating 5-week periods of metho­
trexate and mercaptopurine and 2-w eek periods of vin­
cristine and dexamethasone. In the first year of mainte­
nance, triple intrathecal therapy was administered every  
7 weeks.
Results: From December 1, 1984 until Ju ly  1, 1988,
IN 1984, the Dutch Childhood Leukemia Study Group (DCLSG) started a population-based study in the 
Netherlands for children with non-high-risk acute 
lymphoblastic leukemia (ALL) based on the classic St 
Jude protocols. This study, ALL VI, closely resembled the 
preceding DCLSG ALL V study.1 However, the results of  
the ALL V protocol had proved disappointing in terms 
of event-free survival (EFS; 54.7% ±  4.5% for group A  
and 62.5% ±  4.5% for group B at 5 years) and especially 
the number of CNS relapses, which had been high (18%). 
Moreover, at the time protocol ALL VI was drafted, it 
had become apparent that cranial irradiation had un­
wanted late side effects.2,3 Therefore, a combination o f  
three alternative methods for presymptomatic CNS treat­
ment was used in ALL VI. The first was the use of intrave­
nous medium high-dose methotrexate (2 g/m2 in 24 hours 
for three courses) with citrovorum factor rescue after 36 
hours.4,5 The second was the prolonged administration of  
triple intrathecal therapy during the first year of mainte­
nance.6,7 The third was the use of dexamethasone in in­
duction and in pulses during maintenance instead of the 
standard corticosteroid prednisone. This change was 
based on the experience of Cancer and Leukemia Group 
B (CALGB),8 which demonstrated in a randomized study 
significantly less CNS relapses if dexamethasone was 
substituted for prednisone in a supposedly equivalent dos-
291 children with ALL w ere diagnosed; 206  w ere catego­
rized as n o n -h igh -risk  (71% ), and 190 w ere treated ac­
cording to protocol ALL VI. At 8 years, the event-free 
survival (EFS) rate was 81%  (SE =  3%) and survival rate 
85%  (SE == 2.9% ); the median follow -up time w as 7.3  
years (range, 36 to 117 months). The CN S relapse rate 
w as 1.1% (two of 184 patients who achieved a complete 
remission [CR]). The only factor found to be of negative 
prognostic importance in terms of EFS (P =  .05) was a 
positive acid phosphatase reaction.
Conclusion: For children with n o n -h igh -risk  ALL, the 
combination of IV medium high-dose methotrexate (2 g/  
m2 times three), triple intrathecal therapy in the first year 
of maintenance treatment, and the use of dexam etha­
sone for induction and pulses during maintenance treat­
ment has proved to be highly effective, especially in the 
prevention of CN S relapse. A  high cure rate w as achieved 
without the use of anthracyclines, a lkylating agents, and 
cranial irradiation.
J CHn Oncof 14:911 -918. © 1996 by American So ­
ciety of Clinical Oncology.
age. In protocol ALL VI, cranial irradiation was omitted. 
All patients were treated uniformly and there was no 
randomization, as it was projected that with current results 
an answer to a two-arm study would not be obtained 
within a reasonable time span, considering the patient 
numbers in the Netherlands (the annual accrual rate is 
approximately 65 new cases with non-high-risk ALL).
Thus, the primary goal o f  this study was to improve 
the cure rate without cranial irradiation. A second goal 
was to study potential prognostic factors with the aim 
to restrict the non-high-risk group in future treatment 
protocols to patients without risk-increasing characteris­
tics. Preliminary results were published in 1990.9 The 
results o f this protocol for a group of patients that com­
prises 71% of all newly diagnosed patients with ALL in 
the Netherlands during the study period are now reported 
after a median follow-up time o f 7.3 years (range, 36 to
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117 months) (one patient was lost for follow-up evalua­
tion 36 months after study entry).
METHODS
Patients
This nationwide, multicenter study was limited to newly diag­
nosed non-high-risk patients, defined previously in the DCLSG 
protocol ALL V 1 as follows: age 0 to 15 years, initial WBC count 
less than 50 X 109/L, and absence of a mediastinal mass and/or 
cerebromeningeal leukemia at diagnosis, defined as the absence of 
blasts (cytomorphologically) in a CSF specimen collected at diagno­
sis, to be confirmed by the DCLSG laboratory. Also, patients with 
B-ALL, morphologic (French-American-British [FAB] type L3) or 
immunophenotypic (serum immunoglobulin M positivity), were ex­
cluded from the study, as well as patients pretreated with corticoste­
roids and/or cytostatic drugs shortly before the diagnosis of ALL. 
Informed consent was obtained according to institutional guidelines 
before treatment was started.
Diagnosis
The diagnosis of ALL was made by cy to morphologic and cyto- 
chemical examination of blood and bone marrow smears at the local 
institution, followed by confirmation and classification according to 
the FAB criteria by the DCLSG laboratory.10,11 For a diagnosis of 
ALL, 2= 25% blasts in the bone marrow was mandatory. Acid phos­
phatase positivity was determined as previously described.12
Immunophenotyping was performed by the Central Laboratory of 
the Red Cross Blood Transfusion Service for patients diagnosed 
between December 1984 and December 198613 and by the DCLSG 
laboratory for patients diagnosed after 1986.14 The relative DNA 
content per cell was calculated as the DNA index15 by the Depart­
ment of Experimental Therapy of the Netherlands Cancer Institute, 
Amsterdam.
Handmirror cells (HMC) were defined and counted at the DCLSG 
laboratory.16
Karyotyping of leukemic cells was performed in cytogenctic labo­
ratories in the university hospitals.17
The absence of CNS involvement was assessed in a sample of
CSF drawn at diagnosis, sent to the DCLSG laboratory and mixed 
1;1 with transport medium,18 and checked for leukemic cells by 
cytomorphology.19
Treatment
The treatment scheme of the ALL VI study is outlined in Fig
1. Remission induction consisted of vincristine (2 mg/mVwk by 
intravenous [IV] push times six; maximum, 2.5 mg/dose), dexameth- 
asone (6 mg/m2 daily divided into three doses for 4 weeks, then 
tapered off to 0 mg in 10 days), and asparaginase (200 U/kg/d IV 
for 14 days during weeks 5 and 6). On days 15 and 29, methotrexate 
and prednisolone were administered intrathecally in equal doses 
(doses according to age: <  1 year, 6 mg; 1 year, 8 mg; 2 years, 10 
mg; >  3 years, 12 mg).
After complete remission [CR] was achieved, three weekly 
courses of IV methotrexate (2,000 mg/m2: 400 mg/m2 IV push and 
1,600 mg/m2 IV in 24 hours) were administered with intrathecal 
methotrexate and prednisolone 1 hour before each methotrexate push 
injection (dose according to age given in Remission Induction sec­
tion), followed by citrovorum factor rescue and starting at 36 hours 
after the start of each methotrexate infusion (dose adapted to age:
<  2 years, 5 x 5  mg; 2 to 5 years, 5 X 10 mg; 6 years, 5 X 15 
mg; orally at 6-hour intervals)
Maintenance treatment consisted of mercaptopurine (50 mg/m2/d 
orally) and methotrexate (30 mg/m2/wk orally or IV) for 5 weeks, 
alternated with vincristine and dexamethasone (doses as for induc­
tion treatment) for 2 weeks.
During the first year of maintenance treatment, intrathecal triple 
therapy was administered as follows: methotrexate and prednisolone 
(doses as described earlier) and cytarabine (dose according to age:
<  1 year, 15 mg; t year, 20 mg; 2 years, 25 mg; 2= 3 years, 30 
mg) every 7 weeks on the same day as the first dose of vincristine. 
The total duration of treatment was 116 weeks.
During maintenance treatment, Pneumocystis carinii prophylaxis 
was recommended, (trimethoprim-sulphamethoxazole [TMP/SMZ], 
75 to 100 mg TMP/m2/d in one or two doses).
Evaluation Criteria
CR was defined as less than 5% blasts in the bone marrow and 
(recovery of) normal hematopaiesis, absence of blasts in the periph-
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Fig 1. Treatment scheme of 
protocol ALL VI, MD-MTX, me­
dium high-dose methofrexafe; 
DAF, prednisolone; VCR, vin­
cristine; Dexa, dexamethasone; 
L-ASP, asparaginase; 6-MP, 
mercaptopurine; MTX, metho­
trexate; ARA-C, cytarabine; 
BMP, bone marrow puncture; LP, 
lumbar puncture.
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eral blood, and no evidence of disease at any other site. Relapse was 
defined as >  20% blast cells in the bone marrow and/or blast cells 
in the peripheral blood, and/or CNS involvement, and/or leukemic 
infiltrates elsewhere.
CNS relapse was defined as the presence of blasts (cytomorpho- 
logically) in two successive CSF specimens, collected at least 24 
• hours apart without major blood contamination, confirmed by the 
DCLSG laboratory in the second specimen.
Results of treatment were evaluated by bone marrow examinations 
on days 12 and 42, and subsequently every 12 to 14 weeks during 
and up to 3 years after chemotherapy. All slides had to be sent to 
and examined at the DCLSG laboratory. Every 3 months, registration 
forms with data on dosage, toxicity, and results of treatment for 
each patient were sent to the DCLSG Operations Office, For compar­
ison of treatment results achieved by the German Berlin-Frankfurt- 
Miinster (BFM) Group, the BFM risk factor20 for each patient was 
calculated.
Statistical Methods
Event-free survival (EFS) was defined as the time from diagnosis 
to induction failure (no remission at day 42), relapse, death in remis­
sion, or the occurrence of a second tumor. Patients who did not enter 
remission by day 42 were included in the analysis and considered as 
U*eatment failures on day 0. The duration of survival was calculated 
from diagnosis to time of death; the time to latest follow-up evaluation 
was considered a censored observation. All analyses were based on 
data for all patients who entered the study: no patients have been 
excluded for whatever reason (treatment refusal, toxicity, etc).
Survival curves were calculated according to the Kaplan-Meier 
method21,22 and standard errors using Greenwood’s formula.23 The 
statistical significance of differences in life-table curves was deter­
mined by the two-sided log-rank procedure,23 and for ordered vari­
ables by the log-rank test for linear trend.23 To summarize the prog­
nostic importance of a variable for EFS analysis, the following 
information is given: the total number of patients in each category, 
the total number of observed events (0) and the estimate of the 
relative risk of having an event (E) per time unit computed via the 
O/E ratio.23
RESULTS
Patients
From December 1, 1984 to July 1, 1988, 291 consecu­
tive children with ALL were diagnosed; 206 (70.8%) of  
them fulfilled DCLSG criteria for non-high-risk ALL. 
One hundred ninety children (65.3%) were entered onto 
the ALL VI study. Sixteen patients did not enter the study 
by mistake (one patient) or because of institutional choice 
(15 patients). One hundred fifty-two children were treated 
in one of the centers and 38 in a general hospital.
The characteristics of the 190 patients are listed in Table 
1. The majority of patients was between 1 and 9 years old 
(87.9%), had a WBC count less than 10 X 109/L at diagnosis 
(70.0%), had FAB LI morphology (75.3%) and common 
ALL (73.6%), and was treated in a center (80.0%).
Of 16 patients who did not enter the ALL VI study,
11 were 1 to 9 years old (69%), eight had a WBC count 
less than 10 X 109/L at diagnosis (50%), 11 had FAB LI
morphology (69%), 10 had common ALL (63%), and 
they were all treated in a center.
Treatment Results
Treatment results are updated as of April 1, 1995. The 
median follow-up time was 7.3 years (range, 36 to 117 
months). The overall results of treatment are listed in 
Table 2; EFS and survival are shown in Fig 2. The EFS 
estimation at 6 years is 82% (SE =  2,8%); the estimated 
proportion o f  patients stili alive at 6 years after diagnosis 
is 87% (SE =  2.4%), The corresponding estimates at 8 
years are 81% (SE =  3%) and 85% (SE =  2.9%), respec­
tively. The outcome of the 16 patients not included in the 
ALL VI study was slightly worse than of those included 
in the study, but the difference did not reach statistical 
significance.
Induction Tre at men t
Of 190 patients who entered the ALL VI study, 184 
(96.8%) achieved a CR, One patient died of septicemia 
before treatment. Three children died during induction 
treatment: a boy with D ow n’s syndrome died of septice­
mia, another boy died of accidental intrathecal adminis­
tration of vincristine, and a third boy died of veno-occlu- 
sive disease and tumorlysis syndrome after the first 
injection of vincristine. Two children failed to achieve 
remission and died.
Maintenance and Consolidation Treatment
After the induction period, four children died in first 
remission; two of septicemia during maintenance treat­
ment, one during medium high-dose methotrexate treat­
ment unexpectedly overnight at home (no autopsy was 
performed), and one of fungal cerebral abscesses, also 
during maintenance treatment.
Treatment modifications occurred in four patients. In 
one patient, medium high-dose methotrexate application 
was delayed for 2 months because o f severe liver function 
disturbances. In two patients, maintenance treatment was 
terminated after 1 year because of severe liver toxicity in 
one and recurrent severe infections in the other. In one 
patient, maintenance treatment was interrupted for 2 
months because of complicated appendicitis,
Twenty-five of 184 patients who achieved CR relapsed: 
22 (12%) had an isolated bone marrow relapse and three 
(1.6%) an extramedullary relapse (two CNS [1.1%] and 
one testis [0.5%]) (Table 2), Nine children relapsed dur­
ing treatment (eight bone marrow and one CNS) and 
16 children relapsed after cessation of therapy (14 bone 
marrow, one CNS, and one testis). No combined bone 
marrow/CNS relapses occurred.
The prognosis after relapse was poor; the median sur-
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Table 1. Patient Characteristics
Variable No. of Patients %
Age, years
<  1 1 0.5
1 9 4.7
2-5 115 60.5
6-9 43 22.6
10*15 22 11.6
Sex
Male 98 51.5
Female 92 48.5
WBC count {X 10VL)
< 10 133 70.0
10-24 43 22.6
25-49 14 7.4
Platelet count (X 10?/L)
< 20 36 19.0
20-99 94 49.7
& 100 59 31.2
Unknown 1 —
FAB morphology
L-1 143 75.7
L-2 46 24.3
Unknown 1 --------
Acid phosphatase reaction
Strong 14 8.4
Weak 18 10.8
Negative 134 80.7
Unknown 24 —
Immun ophenotype
c-ALl 130 81.3
Pre-B AIL 25 15.6
AUL 5 3.1
Unknown 30 —
Institution
Center 152 80.0
General hospital 38 20.0
BFM risk factor
<  0.8 103 57.0
0.8-1.19 63 34.8
^  1.2 15 8.2
Unknown 9 —
Cytogenetics
Diploid 40 33.3
Hypodiploid 7 5.8
Pseudodiploid 15 12.5
Hyperdiploid (46-50) 18 15.0
Hyperdiploid (>  50) 32 26.7
Other 8 6.7
Unknown 70 --------
Cytogenetics structure abnormality
6q- 8 6.7
HB;14) 1 0.8
Other 40 33,6
None 70 58.8
Unknown 71
DNA index
<  1.16 85 68.0
1.16 40 32.0
Unknown 65 --------
HMC (%}
< 5 58 47.5
5-9 24 19.7
10 40 32.7
Unknown 68
% &M blasts ah day 12
<  5 75 51.7
5-19 38 26.2
a  20 32 22.1
Unknown 39 —
Abbreviations: AUL, acute undifferentiated leukemia; BM, bone marrow.
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Table 2. Results of Treatment (April 1, 1995) in the ALL VI Study
Period of accrual 1 2 /8 4 -7 /8 8
Total no. o f patients 190
Deaths before treatment 1
Deaths during induction 3
No response 2
CR rate
No. 184
% 96.8
Relapse 25
Site
BM 22
CNS 2
Testis 1
Second tumor r
Deaths in first CR 4
Alive in first CR 155
Follow-up duration
Range, months 36-117
Median, years 7.3
"Second tumor after CNS relapse.
vival time is 25 months. Of 25 patients who relapsed, 15 
(60%) died. The median estimates of survival postrelapse 
were significantly shorter for patients who relapsed on 
therapy (n =  9) than for those who relapsed off therapy 
(n = 16) (5 and 36 months, respectively; P  =  .008). One 
child died of a secondary malignancy (acute nonlympho- 
cytic leukemia) after relapse.
Treatment was well tolerated and in general could be 
given on an outpatient basis. However, in the dexametha- 
sone periods, obesity, sleep disorders, and character dis­
turbances were more pronounced than in the previous 
study using prednisone.
Prognostic Factors
When the ALL VI study started, it was planned to 
evaluate a considerable number of prognostic factors, as 
follows: immunophenotype, D N A  ploidy, karyotype, bone 
marrow at day 12, and HMC percentage. However, because 
of the limited number of patients (N = 190), and especially 
the paucity of events (35 in total), the chance to detect a 
given prognostic factor is low. This is particularly true if a 
variable has many nonordered categories (ie, cytogenetics). 
On die other hand, dividing patients according to too many 
variables, one may obtain, just by chance, a significant result 
at the conventional alpha level o f .05.
To choose a limited number of factors to analyze, the 
previous study of the DCLSG, ALL V, in which the same 
eligibility criteria were used, was analyzed.1 Indeed, in 
this study, in which 240 patients were entered and 101 
events reported, three factors appeared to be associated 
with a worse prognosis by univariate analyses: strong/ 
weak acid phosphatase reaction (P = .0001), high WBC 
count (P =  .0002), and low platelet count (P — .01). For
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Fig 2. Kaplan-Meier curve of 
EFS and survival.
(years)
Number o f  patients at risk :
190 175 170 147 46 Survival
190 171 J56  135 34 EFS
this reason, we have particularly looked at these factors 
to see if they were still of prognostic importance in the 
present study, as well as at the DNA index24,25 and early 
bone marrow response to induction treatment.26,27
Table 3 shows that the acid phosphatase reaction was 
still of weak prognostic importance in this study (P — 
.05): the stronger the reaction, the worse the prognosis. 
Those with a strong positive reaction, representing 14 
of 166 [8.4%] patients in the population, had a 2 .8-fold
Table 3, Prognostic Factors Analysis for EFS
No. of 
Palienls
No. of 
Events
Relative
Risk P*
A cid  phosphatase reaction
Negative 134 20 1.00
W eak 18 3 1.16 .05
Strong 14 5 2.83
W BC count (x  109/L)
<  10 133 21 1.00
10-24 43 12 1.87 .40
25-49 14 2 0.87
Platelet count (X 109/L)
<  20 36 8 1.00
20-99 94 19 0.91 .16
ooAl 59 7 0.50
D N A  index
<  1.16 85 17 1.00
5: 1.16 40 4 0.47 .16
*Log-rank test for linear trend.
increased risk of failure compared with those with a nega­
tive reaction (134 of 166 [80.7%]). Where in ALL V the 
initial WBC count was linearly correlated with a worse 
prognosis, this was not the case in ALL VI (P = .38): 
patients with a WBC count of 10 to 24 X  10y/L seem to 
have a worse prognosis (relative risk, 1.93) than those with 
a low WBC count ( <  10 X  109/L), but patients with the 
highest values (WBC count 25 to 49 X  10y/L), have a 
similar prognosis (relative risk, 0.90) as those with a low 
WBC count. The initial platelet count seems to be correlated 
with prognosis, although it does not reach statistical signifi­
cance. Like in the ALL V study, patients with a normal 
platelet count at diagnosis have an approximately 50% re­
duction in the risk of having an event compared with those 
with a very low ( <  20 X  109/L) or low (20 to 99 X  109/  
L) platelet count. Conversely, one may say that patients 
with a diminished platelet count have a twofold increased 
risk of having an event. Patients with a high DNA index 
(s= 1.16), who represent 32% of the patients entered onto 
the study, have a relative risk of 0.46 compared with those 
with a low D N A  index (<  1.16). Due to the low number 
of events (21 in total), one may not conclude that the true 
relative risk is statistically different from 1 (P =  .14).
Finally, day-12 bone marrow findings (<  u s  5% blast 
cells) were of no prognostic significance. However, an 
important group of patients (39 of 184 [21%]) either had 
a hypoplastic bone marrow or bone marrow puncture was 
not performed. Among available patients, 52% (75 of
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145) were good responders (<  5% blasts at day 12), 
whereas the remaining patients responded poorly. The 
outcome of these two groups, in terms of disease-free 
survival, was similar in this series (relative risk, 1.04).
DISCUSSION
The results of protocol ALL VI for children with non-  
high-risk ALL are encouraging, with a projected long­
term cure rate of 80%. The EFS rate at 6 years is 82%, 
In particular, the number of CNS relapses (n =  2) and 
other extramedullary relapses (testes, n =  1) was low. 
The most important cause for treatment failure was iso­
lated bone marrow relapse. Nine (5%) of 190 patients 
experienced treatment-related toxicity (four very early).
The ALL VI study was preceded by the ALL V study 
(1979 to 1982) with identical criteria for patient eligibil­
ity.1 In both studies, vincristine and asparaginase were 
given during induction, but in the ALL V study, predni­
sone (40 mg/m2/d orally) was given instead of dexametha- 
sone (6 mg/m2/d orally). CNS prohylaxis in the ALL V 
study consisted of cranial irradiation (dose according to 
age: <  I year, 15 Gy; 1 to 2 years, 20 Gy; ^  2 years, 
25 Gy) with five courses of intrathecal administration of 
methotrexate and prednisolone (12.5 mg/m2/dose; maxi­
mum, 15 mg/dose), compared with intrathecal methotrex­
ate and prednisolone on day 15 and 29 of induction treat­
ment, three courses of IV medium high-dose methotrexate 
after CR, and continuation of intrathecal triple therapy 
during the first year of maintenance in the ALL VI study. 
Furthermore, patients in ALL V were randomized to re­
ceive rubidomycin (four weekly doses, 25 mg/m2) during 
induction treatment (group B [n =  118]) or not to receive 
this fourth drug (group A [n =  122])* In the ALL V study, 
the EFS rate at 1.0 years for group A was 49% (SE =  
4.5%) and for group B 56% (SE =  4.5%) (P =  .07). In 
both groups, the number of CNS relapses (19 in group 
A and 12 in group B) was as high as the number of bone 
marrow relapses (20 in group A and 13 in group B). 
There were six combined relapses (bone marrow plus 
CNS) in group A and four in group B.
The combination of IV medium high-dose methotrexate 
(three times), prolonged intrathecal therapy, and substitution 
of prednisone by dexamethasone has proved to be highly 
effective in preventing CNS relapse and thus improving 
overall treatment results in non-high-risk ALL patients. The 
efficacy of IV methotrexate in the CNS depends on the 
duration of exposure above a specific threshold of the drag 
in plasma ( > 2 4  hours, >  1 X 10~6mol/L), the plasma 
concentration (CSF-to-plasma ratio, 2% for methotrexate), 
and concurrent intrathecal methotrexate at the start of the 
infusion.28'32 Intermediate-, medium-, and high-dose 24-hour 
IV infusions of methotrexate with citrovorum factor rescue
have been applied in many studies in the last decade to 
increase treatment efficacy and, serving as a substitute for 
cranial irradiation, to decrease toxicity.4^ *33
In St Jude Total Therapy Study X, high-dose metho­
trexate (15 courses at 1,000 mg/m2) was compared with 
cranial irradiation.34 CR durations at 4 years were sig­
nificantly longer in the methotrexate group (67% v 56%), 
with a lower rate of isolated bone marrow and testicular 
relapses compared with the irradiated group, but no dif­
ference in the occurrence of CNS relapse was observed. 
In a nonrandomized study, the Pediatric Oncology Group 
(POG) investigated the effectiveness of early intensifica­
tion with a combination of high-dose IV methotrexate 
and mere ap top urine to take advantage of the synergy 
of these drugs and with the objective to decrease CNS 
relapses.35,36 At 7 years, only one CNS relapse had oc­
curred in 59 lower-risk patients; the EFS of this group 
had a plateau at 82.4% ±  7.5%. In the higher-risk group 
(n =  83), nine patients suffered a CNS relapse. The EFS 
rate at 4 years of this higher-risk group was 57.4% ±  
9J%. The incidence of CNS relapse in both groups to­
gether was 11%, which is slightly higher than the 5% to 
9% observed in previous POG studies. In the current 
DCLSG protocol ALL 8, a prospective randomized study 
is being performed to determine the effectiviness of the 
addition of conventional oral mercaptopurine versus IV 
high-dose mercaptopurine to high-dose methotrexate in­
fusions as early intensification in medium-risk ALL pa­
tients .
Intrathecal methotrexate therapy during induction, con­
solidation, and maintenance treatment, which was associ­
ated with intensive systemic therapy in study CCG 105, 
provided a CNS relapse-free survival rate at 7 years of 
91% for 507 intermediate-risk ALL patients.37
Triple intrathecal chemotherapy (methotrexate, cytara- 
bine, and hydrocortisone), extended throughout the inten­
sification and maintenance periods plus upfront intrathe­
cal methotrexate for patients with B-progenitor ALL has 
proved to be even more effective in prevention of CNS 
relapse. In the POG ALinC 13 study, the estimation of 
freedom from isolated CNS relapse in 381 good-risk non- 
B-, non-T-ALL patients, which consists of 58% of all 
ALL patients, was 97.2% (±  1.3%) at 5 years.38 The 
higher effectivity of dexamethasone compared with pred­
nisone is probably based on a combination of factors: 
dexamethasone has a longer duration of biologic action, 
less protein binding capacity leading to increased plasma 
free drug availability to lymphoblasts, and better penetra­
tion to CSF and a longer CSF half-life than prednisone.39 
In vitro drug-sensivity testing has shown that dexametha­
sone appears to be sevenfold more potent than predni­
sone.40 The results o f  the ALL VI study confirm the data
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reported by Jones et al,8 who found a considerable reduc­
tion of CNS relapses in a randomized trial o f dexametha- 
sone versus prednisone.
One of the aims of this study was to identify prognostic 
factors. However, with 190 patients and 35 events, leading 
to an estimated EFS rate of 80% at 7 to 8 years, it was 
difficult to reach this goal; with increasingly effective ther­
apy, prognostic factors tend to lose their significance.
It must be kept in mind that non-high-risk status ac­
cording to the criteria applied in ALL VI still leaves 29% 
of all children with ALL out of the study. Given the 
unequal criteria and composition o f  non-high-risk, stan- 
dard-risk, and low-risk groups in other protocols, one 
might ask what the results are of all children with ALL 
(0 to 15 years) diagnosed in the accrual period of the 
ALL VI study. In the Netherlands at that time, high-risk 
patients were treated according to institutional protocols, 
some of which were based on the German BFM treatment 
strategy. The estimated EFS rate at 6 years for the total 
291 children newly diagnosed with ALL in this period 
in the Netherlands was 72% (SE = 3 % ).
These overall data compare well with the overall results 
o f other groups, including the BFM (69%)28 and the Dana- 
Farber Cancer Institute (DFCI; 70%).41,42 They are in the 
same range as the outcome data for recently treated chil­
dren with B-precursor ALL in the combined POG and 
Childrens Cancer Group studies, in which the 4-year EFS
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